<DOC>
	<DOCNO>NCT02093585</DOCNO>
	<brief_summary>Some observational study find current exposure abacavir associate increase risk cardiovascular event myocardial infarction , stroke cardiovascular death . This study aim investigate possible adverse effect abacavir platelet reactivity , coagulation endothelial activation HIV-1 infect patient . The study open-labeled cross-over trial , patient receive antiretroviral therapy contain abacavir switch treatment regimen contain tenofovir vice versa period 90 day .</brief_summary>
	<brief_title>Tenofovir Abacavir Platelet Activation Study</brief_title>
	<detailed_description />
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Dideoxynucleosides</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>HIV1 infect Can understand sign write informed consent Received one mention antiretroviral regimen continuously ≥ 6 month HIV RNA &lt; 400 copies/mL ≥ 6 month Receiving anticoagulant therapy , adenosine diphosphate ( ADP ) receptor inhibitor , aspirin nonsteroidal antiinflammatory drug ( NSAIDs ) Previous ischemic heart disease , peripheral atherosclerotic disease stroke Coagulation disorder ( e.g . hemophilia , factor V Leiden mutation ) Platelet count &lt; 150 x 109/L past 6 month inclusion Estimated glomerular filtration rate ( eGFR ) &lt; 70 past 6 month inclusion Humane leukocyte antigen ( HLA ) B*57:01 positive genotype Hepatitis B C positive past year inclusion Hypersensitivity active substance excipients</criteria>
	<gender>Male</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Abacavir</keyword>
	<keyword>Platelet activation</keyword>
	<keyword>Thromboelastography</keyword>
	<keyword>Coagulation</keyword>
</DOC>